Financial Results along with the Limited Review Report of Novartis India Limited for the quarter ended June 30, 2026.
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 23 Jul 2026, 01:04 PM IST · BSE ID: 1387d543-2e1b-4a68-b928-ad167669b855
View Original BSE Filing (PDF)
💡
In Simple Terms
Novartis India's latest financial report shows no outstanding debt or defaults as of June 30, 2026.
🤖 AI Summary
- Novartis India Limited submitted unaudited financial results for the quarter ended June 30, 2026.
- The company reported NIL total financial indebtedness, covering both short-term and long-term debt.
- NIL amount outstanding and NIL amount of default on loans from banks/financial institutions as of date.
- NIL amount outstanding and NIL amount of default on unlisted debt securities (NCDs and NCRPS).
- The filing includes the Limited Review Report by the Statutory Auditors for Q1 FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Loans / revolving facilities outstanding as on date
NIL (INR)
Loans / revolving facilities default as on date
NIL (INR)
Unlisted debt securities outstanding as on date
NIL (INR)
Unlisted debt securities default as on date
NIL (INR)
Total financial indebtedness of the listed entity
NIL (INR)
🏢 How This Affects the Company
The company's balance sheet reflects NIL total financial indebtedness, indicating a debt-free status for both short-term and long-term obligations as of the reporting date.
The absence of outstanding loans and debt securities, along with no reported defaults, significantly reduces financial leverage and associated default risks for the company.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All existing shareholders are indirectly affected by the company's confirmed debt-free status, as it implies lower financial risk and potential for greater financial flexibility.
🔍
Management Signal
The management's report of NIL financial indebtedness signals a continued focus on maintaining a strong balance sheet and avoiding external debt.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 unaudited results — review for continued NIL financial indebtedness.
Next annual report — examine balance sheet details for debt strategy consistency.
Board meeting outcomes — monitor for any decisions impacting financial structure.
LOW RISK
The company has reported NIL financial indebtedness and no defaults, indicating a low financial risk profile.
💡 Investor Takeaway
Novartis India Limited reported NIL total financial indebtedness for the quarter ended June 30, 2026, with NIL outstanding loans from banks and NIL unlisted debt securities. This confirms a debt-free status for the reporting period.
⚖️ Strengths & Concerns
✅ Positives
- Total financial indebtedness of the listed entity, including short-term and long-term debt, is NIL as of June 30, 2026.
- No outstanding amounts or defaults reported for loans/revolving facilities from banks/financial institutions or unlisted debt securities.
📅 Company Track Record
Novartis India reported NIL total financial indebtedness for the Financial Year ended March 31, 2026, as per its filing on May 12, 2026. This current filing for Q1 FY27 indicates a continuation of this debt-free status.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is Novartis India's total financial indebtedness for the quarter ended June 30, 2026?
Novartis India Limited reported NIL total financial indebtedness, including short-term and long-term debt, for the quarter ended June 30, 2026.
Does Novartis India have any outstanding loans from banks as of June 30, 2026?
As of June 30, 2026, Novartis India Limited reported NIL total amount outstanding for loans or revolving facilities from banks and financial institutions.
Are there any defaults on unlisted debt securities for Novartis India in Q1 FY27?
Novartis India Limited reported NIL amount of default on unlisted debt securities, such as NCDs and NCRPS, for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.